Based on the GH Research PLC stock forecast from 2 analysts, the average analyst target price for GH Research PLC is USD 39.50 over the next 12 months. GH Research PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of GH Research PLC is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, GH Research PLC’s stock price was USD 8.97. GH Research PLC’s stock price has changed by +4.06% over the past week, +23.72% over the past month and +18.03% over the last year.
No recent analyst target price found for GH Research PLC
No recent average analyst rating found for GH Research PLC
Company Overview GH Research PLC
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Read Less
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of pat...Read More
Frequently Asked Questions About GH Research PLC (GHRS) Stock
Based on ratings from 2 analysts GH Research PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on GHRS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for GHRS is USD 39.50 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 39.
Unfortunately we do not have enough data on GHRS's stock to indicate if its overvalued.
The last closing price of GHRS's stock was USD 8.97.
The most recent market capitalization for GHRS is USD 0.42B.
Based on targets from 2 analysts, the average taret price for GHRS is projected at USD 39.50 over the next 12 months.
This means that GHRS's stock price may go up by +340.36% over the next 12 months.
We can't find any ETFs which contains GH Research PLC's stock.
As per our most recent records GH Research PLC has 49 Employees.
GH Research PLC's registered address is Joshua Dawson House, Dublin, Ireland, D02 RY95.
You can get more information about it from GH Research PLC's website at https://www.ghres.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About GH Research PLC (GHRS) Stock
Based on ratings from 2 analysts GH Research PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on GHRS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for GHRS is USD 39.50 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 39.
Unfortunately we do not have enough data on GHRS's stock to indicate if its overvalued.
The last closing price of GHRS's stock was USD 8.97.
The most recent market capitalization for GHRS is USD 0.42B.
Based on targets from 2 analysts, the average taret price for GHRS is projected at USD 39.50 over the next 12 months.
This means that GHRS's stock price may go up by +340.36% over the next 12 months.
We can't find any ETFs which contains GH Research PLC's stock.
As per our most recent records GH Research PLC has 49 Employees.
GH Research PLC's registered address is Joshua Dawson House, Dublin, Ireland, D02 RY95.
You can get more information about it from GH Research PLC's website at https://www.ghres.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GHRS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
